AKBA Jan 2025 0.500 call
| Previous Close | 0.5900 |
| Open | 0.5900 |
| Bid | 0.0000 |
| Ask | 0.0000 |
| Strike | 0.50 |
| Expire Date | 2025-01-17 |
| Day's Range | 0.5900 - 0.5900 |
| Contract Range | N/A |
| Volume | |
| Open Interest | N/A |
PR NewswireAkebia Therapeutics to Present at the H.C. Wainwright 3rd Annual Kidney Virtual Conference
Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that John Butler, Chief Executive Officer, will participate in the H.C. Wainwright 3rd Annual Kidney Virtual Conference on Monday, July 15, 2024. Mr. Butler will present at 9:30 a.m. ET to provide updates on the progress of commercial launch activities for Vafseo® (vadadustat) Tablets.
- PR Newswire
Akebia Therapeutics Appoints Erik Ostrowski as Chief Financial Officer and Chief Business Officer
Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced the appointment of Erik Ostrowski as Senior Vice President, Chief Financial Officer and Chief Business Officer. Mr. Ostrowski is an experienced biotech executive with a diverse background spanning industry leadership roles, board service and investment banking.
Simply Wall St.Further weakness as Akebia Therapeutics (NASDAQ:AKBA) drops 16% this week, taking five-year losses to 80%
Long term investing is the way to go, but that doesn't mean you should hold every stock forever. We don't wish...
